Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bob Dole pushes MIRA

This article was originally published in The Gray Sheet

Executive Summary

Former Kansas senator is helping to publicize the "Medicare Innovation Responsiveness Act." Dole, who was implanted with an endograft to treat an abdominal aortic aneurysm, appeared at a recent press event introducing the bill. HR 941, sponsored by Reps. Jim Ramstad (R-Minn.) and Anna Eshoo (D-Calif.), would establish a CMS Council for Technology & Innovation and extend Medicare coverage to IDE trials (1"The Gray Sheet" March 3, 2003, p. 8)...

You may also be interested in...



MIRA Bill Calls For One-Year Ceiling On National Coverage Decisions

Pending Medicare coverage requests for positron emission tomography (PET) additional indications will need to be resolved rapidly if the "Medicare Innovation Responsiveness Act of 2003" is signed into law

Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines

Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018027

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel